Ocera Therapeutics Inc. (NASDAQ:OCRX) dropped 11.3% during trading on Friday . The stock traded as low as $2.15 and last traded at $2.27, with a volume of 464,113 shares. The stock had previously closed at $2.56.

OCRX has been the subject of several analyst reports. Zacks Investment Research upgraded Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research note on Tuesday, April 26th. Brean Capital restated a “buy” rating on shares of Ocera Therapeutics in a research note on Tuesday, April 12th.

The stock’s market capitalization is $51.26 million. The firm has a 50-day moving average of $2.43 and a 200 day moving average of $2.72.

Ocera Therapeutics (NASDAQ:OCRX) last announced its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.02. On average, analysts expect that Ocera Therapeutics Inc. will post ($1.36) earnings per share for the current fiscal year.

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.